French Cancer Specialist Innate Pharma Can Remain Independent, For Now: CEO

France's Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being and will seek co-development deals modeled on an agreement struck with AstraZeneca in April.

Innate sees its independence as key to delivering optimum shareholder value in a sector characterized by big-money deals as large drugmakers look to acquire new, effective cancer treatments. In August Pfizer announced the $14 billion purchase of Medivation Inc, adding its blockbuster prostate cancer drug Xtandi to a growing oncology portfolio.

Back to news